A Systematic Analysis of Studies on Corona Virus Disease 19 (COVID-19) from Viral Emergence to Treatment

Shahzadi Misbah¹, Abrar Ahmad¹, Muhammad Hammad Butt¹, Yusra Habib Khan², Nasser Hadal Alotaibi² and Tauqeer Hussain Mallhi²

¹Faculty of Pharmacy, University of Central Punjab, Lahore, Pakistan
²Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Al-Jouf Province, Kingdom of Saudi Arabia

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created tremendous panic around the globe amid rapid transmission and high mortality. The virus emerged from China in December 2019 and spread to over 200 countries. The number of cases in USA and Europe has surpassed that of China. Epidemiologists believe that more cases and deaths may occur till undefined time period. During the current health crisis when scientific community is battling hard to contain the COVID-19, provision of timely and authenticative information in a composite document based on recent findings carries substantial value. To the best of authors’ knowledge, there is no comprehensive review on COVID-19 till date. In this context, current manuscript is aimed to provide amalgamated information in a single document to healthcare professionals, researchers and the general public regarding the outbreak-turned-pandemic of COVID-19. This systematic review discusses epidemiology, pathogenesis, transmission, clinical manifestations, severity, treatment, prevention, vaccination, medication repositioning, potential drug candidates, and control and public awareness of COVID-19.

Key Words: COVID-19, Pandemic, Epidemiology, Virology, SARS-CoV-2, World Health Organization, Corona Virus.

How to cite this article: Misbah S, Ahmad A, Butt MH, Khan YH, Alotaibi NH, Mallhi TH. A Systematic Analysis of Studies on Corona Virus Disease 19 (COVID-19) from Viral Emergence to Treatment. J Coll Physicians Surg Pak 2020; 30(Supp):S9-S18 https://doi.org/10.29271/jcpsp.2020.Supp.S9.

INTRODUCTION
Coronaviruses belong to family coronaviridae with well-structured envelopes and plus-strand RNA. Numerous species of this family have been involved in various infections. The pathogenicity of these viruses is not limited to humans only, but has also extended to animals including bats, rats, cattle, rabbits, dogs, swines, chickens, cats, turkeys, mice and horses. Table (I) describes the details of some important viruses of this family. Viral contract results in various respiratory and digestive disorders. The discovery of HCoV-OV43 and HCoV-229E dated back to 60’s and have been recently known to cause common cold.1,2

Previously, these viruses were known to cause mild to moderate infection in humans and were not considered as highly pathogenic, until the Severe Acute Respiratory Syndrome (SARS) outbreak emerged in China during 2003 and 2004. In 2012, another outbreak by a highly pathogenic virus named MERS-CoV (Middle East Respiratory Syndrome Coronavirus) was reported in Saudi Arabia.3 In 2019, when Middle Eastern countries were putting their efforts to combat the MERS, another novel coronavirus SARS-CoV-2 emerged in Wuhan, China (Figure 1). World Health Organization (WHO) coined the name of COVID-19 following its rapid spread to the other countries and declared it pandemic. Scientific communities around the globe are battling hard to provide scientific evidences related to COVID-19 in order to curb the growing encumbrance of the infection.

To the best of authors’ knowledge, there is no composite document with comprehensive information of infection and virus till the uniting of this manuscript. Keeping in view the overwhelmed healthcare system and extensive burden on health professionals, timely and authenticative information carries substantial value. In this context, a comprehensive draft on recent findings will be of paramount importance and may aid to extract useful information during limited time.

The aim of the current manuscript was to provide a systematic review of recent findings on the virus structure and genome, modes of transmission, disease epidemiology, clinical manifestations, diagnosis, complications, management, and public awareness and response.

SEARCH METHODOLOGY:
This current review included the recent advances in the research of COVID-19 to provide precise and comprehensive information on several aspects ranging from emergence of virus to treatment and prevention. All the required information were collected via an electronic search of different scientific...
sources including PubMed (http://www.ncbi.nlm.nih.gov/pubmed), Science Direct (http://www.sciencedirect.com/), Google Scholar (http://scholar.google.com/), Scientific Electronic Library Online (SciELO) (http://www.scielo.org/), Cochrane Library (http://www.cochranelibrary.com/), and Web of Science (http://www.webofknowledge.com/). The study data-base encompassed articles of peer-reviewed journals, books, thesis, dissertations, various patents and supplementary reports covering all aspects of COVID-19 from date of inception to May 2020. Since many updates on COVID-19 are also distributed through news, current review also included these sources if scholarly paper was not found.

Authors opted the following keywords to find the relevant studies:

- SARS-CoV-2
- Corona Virus
- Coronavirus Disease
- COVID-19
- SARS
- nCoV
- Corona Infection
- Wuhan Coron
- SARS-CoV-2
- FDA
- World Health Organization
- Centre for Disease Control and Prevention
- Treatment and Prevention
- Vaccination
- Chloroquine
- Hydroxychloroquine
- Virus replication
- Clinical Manifestation
- Complications
- Drug Repurposing
- Social distancing
- Sanitizer
- Ivermectin
- Disinfectant
- COVID-19 mortality
- Pneumonia
- Acute respiratory distress syndrome
- pulmonary disease

Authors. The inclusion of study in the review was based on full text assessment. Dissent among researchers concerning the worth of studies was resolved through discussion and mutual consent. The information extracted from these studies was discussed in various headings and subheadings.

Table I: Several species of coronaviruses and its emergence around the globe.

| Name of CoV | Genus | Year of outbreak | Place of outbreak | Distribution of virus (Countries/spread/ deaths) | Incubation period | Reference |
|-------------|-------|-----------------|------------------|------------------------------------------|------------------|-----------|
| Human CoV-229E | Alpha | 1966 | United State of America | Globally | 2-5 days | 65, 66 |
| Human CoV-NL63 | Alpha | 2004 | Netherland | Globally | 2-4 days | 65, 67 |
| Human CoV-HKU1 | Beta | 2005 | Hong Kong | Globally | 2-4 days | 65, 68 |
| Human CoV-OC43 | Beta | 1967 | United State of America | Globally | 2-5 days | 65, 69 |
| SARS-CoV | Beta | 2002-2003 | China | Globally (26/8000/7740) | 2-11 days | 65, 70 |
| MERS-CoV | Beta | 2012 | Saudi Arabia | Globally (2724/4858) | 2-13 days | 65, 71 |
| SARS-CoV-2 | Beta | 2019 | China | Globally (204/634/835/29957) | 2-14 days | 33, 72-74 |

*Includes territories, overseas dependencies areas, and other jurisdictions of similar status.

CoV = Corona virus.

An overview of COVID-19 emergence and spread:

A cluster of pneumonia patients with unknown etiology was observed on December 2019, in Wuhan (Hubei province), China. Initially, the disease was thought to be originated from the wild animals in wet market (known as Huanan Seafood wholesale Market), as most of the patients who experienced symptoms had history of visiting the market. Several hypotheses claimed that the virus is mutated and transferred from animals to humans, resulting in the first cluster. The virus was rapidly transmitted to family members and health professionals, indicating the contagious nature of the disease. Early evidences suggested that virus can transfer through close contact via air droplets and fomite. Initially, the morbidity of COVID-19 remained relatively low but the dramatic increase in confirmed cases was observed in the mid of January, with disease spillover to the adjacent regions. The virus spilled to the other parts of the world instantly amid enhanced community movements and travelling for Chinese New Year. The causative agent was identified with deep sequencing analysis in the samples extracted from lower respiratory tract and was designated as 2019-nCoV (2019 novel Coronavirus) by WHO. The scientific community around the globe responded quickly and recognized genomic sequence of the virus. The scientific community around the globe responded quickly and recognized genomic sequence of the virus. The scientific community around the globe responded quickly and recognized genomic sequence of the virus.

Global spread - response and actions:

The outbreak was declared a Public Health Emergency of International Concern (PHEIC) by the WHO on January 30, 2020 following its spread to nineteen countries including mainland of China. The Coronavirus Study Group of the International Committee on Taxonomy of Viruses proposed the virus name as ‘Severe Acute Respiratory Syndrome Coronavirus 2’ (SARS-CoV-2) following its gene sequencing. The name of disease as...
COVID-19 (Coronavirus Disease 2019) was suggested by WHO on February 11, 2020. Keeping in view the spread of disease to more than 100 countries, WHO declared pandemic on March 11, 2020. Despite vigorous manoeuvres to contain the virus, the disease transmitted to all major regions of WHO at the end of April.

### Table II: Severity criteria of confirmed COVID-19 pneumonia

| Types       | Findings                                                                 |
|-------------|--------------------------------------------------------------------------|
| Mild        | Mild clinical symptoms [fever <38°C (quelled without treatment), with or without cough, no dyspnoea, no gasping, no chronic disease] No imaging findings of pneumonia |
| Moderate    | Respiratory symptoms, Fever, imaging findings of pneumonia               |
| Severe      | Meet any of the followings: Respiratory distress, respiratory rate ≥30 times/min Oxygen saturation (SpO2) <93% at rest Partial pressure of oxygen (PaO2) / fraction of inspired oxygen (FiO2) ≤ 300 mmHg Patients showing a rapid progression (>50%) on CT imaging within 24-48 hours should be managed as severe. |
| Critical    | Meet any of the followings: Respiratory failure, need mechanical assistance Shock “Extra pulmonary” organ failure, intensive care unit is needed |

The genomic structure in coronavirus has organization in a +ssRNA having approximate length of 30 kb. It has a 5’-cap structure and 3’-poly-A tail. The viral RNA in the host synthesizes 1a/1ab (pp1a/pp1ab) polyprotein (Figure 4). Transcription occurs by RTC (Replication-Transcription Complex) in a double-membrane vesicle and through sgRNA (sub-genomic RNA) synthesis. Termination of transcription occurs at transcription regulatory sequences that are present between ORFs (open reading frames) which serve as templates to produce sub-genomic mRNAs. In a coronavirus genome, there can be at least 6 ORFs. Of these, a frame shift between the ORF1a and ORF1b guides synthesis of the polypeptides pp1a and pp1ab which are then processed by the 3CLpro (Chymotrypsin-like protease) or the Mpro (Main protease) and up to two papain-like proteases for production of sixteen nsps (non-structural proteins). Other open reading frames encode for the accessory protein chains and structural proteins such as nucleocapsid, membrane, spike and envelope proteins. Varying coronaviruses have special accessory and structural proteins translated by specific sgRNAs. Spike glycoproteins of coronaviruses have two subunits (S1 and S2) which are composed of homotrimers of S proteins. They help the virus in binding to the host receptors which are believed to be membrane-bound angiotensin-converting enzyme 2 (ACE2) in the case of SARS-CoV-2.
Pathogenesis:
The animal reservoir of SARS-CoV-2 is not known yet. However, the genomic characterisation shows similarity of 79% and 50% with SARS-CoV and MERS-CoV, respectively.\textsuperscript{23,24} Regardless of the variations, recent evidences underscore that SARS-CoV-2 uses ACE2 receptor to gain access to the target host cells, same target used by SARS-CoV during pathogenesis.\textsuperscript{24,25} However, the binding affinity of new virus is higher than other Coronaviruses.\textsuperscript{26} ACE2 is a dipeptidyl carboxypeptidase that removes carboxy-terminal hydrophobic or basic amino acids. ACE2 cleaves Angiotensin I, generating Angiotensin 1-9, and Angiotensin II to generate Angiotensin 1-7, which has vasodilating effect opposed to Angiotensin II generated by angiotensin converting enzyme.\textsuperscript{27,28}

A study reported high expression of ACE2 in the oral mucosa, which facilitates the entry of virus in the host.\textsuperscript{29} ACE2 is usually expressed on type 1 and 2 alveolar epithelial cells in the lower lungs. After its infection, SARS-CoV-2 starts to enter alveolar cells through the binding of the spike glycoprotein to ACE2 on the alveolar surface. This binding causes the clathrin-dependent endocytosis of the whole SARS-CoV-2 and ACE2 complex. pH-dependent endosomal cysteine protease cathepsins and low pH facilitates endosomal cell entry of SARS-CoV-2. After entrance into the cell, SARS-CoV-2 exploits the transcriptional machinery of the host alveolar cells for replication, spreading to the entire lung.\textsuperscript{30} When most of the ciliated cells of alveoli are infected, the normal activities of these cells (such as airways clearance) are stopped and progressive accumulation of fluids and debris occurs in the lungs resulting in acute respiratory distress syndrome (ARDS).\textsuperscript{31}

Clinical manifestations:
COVID-19, like other beta coronaviruses, varies in clinical manifestations from mild respiratory anomalies to septic shock. Similar to the SARS and MERS, initial symptoms revolve around dry cough, fever and shortness of breath.\textsuperscript{32} Though diarrhoea has been reported in 20% to 25% of MERS and SARS cases but its prevalence is quite low in COVID-19. However, one study also reported nausea, vomiting, chest pain and confusion along with primary symptoms.\textsuperscript{33} Chest CT and X-ray imaging of COVID-19 cases revealed unilateral or bilateral involvement compatible with viral pneumonia, and bilateral multiple lobular and sub segmental consolidation regions were seen in patients admitted to intensive care unit (ICU).\textsuperscript{34} A study on 41 COVID-19 cases\textsuperscript{9} reported dry cough, fever, fatigue and myalgia in most of the patients while headache, expectoration, diarrhoea and haemoptysis were infrequent in these cases. The study reported that 32% positive cases had comorbid conditions such as hypertension, cardiovascular disease and diabetes mellitus. Patients also developed shortness of breath with abnormal chest CT as well as pneumonia. Subgroup analysis revealed that patients with underlying comorbidities portend severe clinical manifestations as compared to those without any comorbid condition. Available evidence suggest substantial association of disease severity with mortality rate.\textsuperscript{34} The severity criteria of COVID-19 are described in Table (II).\textsuperscript{15}

Laboratory profile:
Patients with COVID-19 present with elevated pro-inflammatory cytokines and abnormal respiratory findings. A case study demonstrated that patient with fever history of 5 days presented with coarse breathing sounds of both lungs, cough and hyperthermia (39°C).\textsuperscript{35} Laboratory studies showed leukopenia with counts of 2.91 x 10^9 cells/L, 70% of which were neutrophils, and increased value of C-reactive protein (16.16 mg/L; normal range, 0–10 mg/L) in blood. Observations also included elevated erythrocyte sedimentation rate (29 mm/h; normal range, <20 mm/h) and D-dimer (580 ng/mL; normal range, 500 ng/mL).\textsuperscript{13} Clinical manifestations of severe COVID-19 include severe pneumonia, RNAaemia with ground--
glass opacities in imaging and acute cardiac injury. Moreover, patients showed significantly high levels of chemokines and cytokines in the blood. These include IL1-β, IL1RA, IL7, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFNγ, IP10, MCP1, MIP1α, MIP1β, PDGFB, TNFo, and VEGFA. Severe patients admitted to intensive care unit (ICU) showed increased levels of pro-inflammatory cytokines including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1α, and TNFα. Studies have elaborated that these cytokines are associated with the disease severity.21

Table III: Comparison of influenza, common cold, MERS, SARS, and COVID-19

| Diseases        | Incubation Period | Respiratory symptoms                                      | Constitutional symptoms          | CT Imaging findings                  | Reference | Vaccines and Drugs | Company Name | Current Status of development |
|-----------------|-------------------|-----------------------------------------------------------|----------------------------------|--------------------------------------|-----------|---------------------|--------------|-----------------------------|
| Common cold     | 1-3 Days           | Stuffy nose, runny noses, sneeze                         | No obvious discomfort            | Usually normal                       | 15        | mRNA vaccine BNT162 | BioNTech Pfizer | mRNA-based vaccine candidate initiated. |
| Influenza       | 1-4 Days           | Stuffy nose, runny noses, sore throat and dry cough      | High fever, muscle ache, malaise | Small patch GGO and consolidation with subpleural and/or peri-bronchial distribution | 75, 76    | COVID-19 S-Trimer   | GlaxoSmithKline and CloveBiopharmaceuticals | Preclinical development is started using GSK’s adjuvants (compounds that enhance vaccine efficacy) and Clove’s proprietary proteins, which stimulate an immune response. |
| SARS            | 2-11 Days          | Cough, dyspnea                                           | Fever, chill, malaise, headache, diaphram | Subpleural GGO and consolidation prominent lower lobe involved, interlobulat sepul and intralobular septal thickening | 77-80     | SARS-COV-2 Vaccine | Johnson & Johnson | Partnering with the Biomedical Advanced Research and Development Authority to develop vaccine candidate. |
| SARS            | 2-11 Days          | Sore throat, dry cough, dyspnea                          | Fever, chill, rigor              | Bilateral, basilar and subpleural airspace, extensive GGO and occasional septal thickening and pleural effusions | 15, 65, 80 | Live-attenuated vaccine | Cohagenix | Co-develop a live-attenuated vaccine. |
| MERS            | 2-13 Days          | Sore throat, dry cough, dyspnea                          | Fever, chill, rigor              | Multifocal patchy GGOs with subpleural distribution. Diffused heterogeneous consolidation with GGO | 4, 33, 81 | Intranasal COVID-19 vaccine | Allimmune, Inc | Design and synthesis has been completed and soon start animal testing. |
| COVID-19        | 2-14 Days          | Cough or not, sore throat, Breathless, respiratory failure| Fever, Fever, muscle ache, confusion, headache | Multifocal patchy GGOs with subpleural distribution. Diffused heterogeneous consolidation with GGO | 11, 22, 87 | HaloVax             | Voltron Therapeutics | Vaccine candidate using microneedle transdermal for COVID-19. Testing in mice produced antibodies over a 2-week period. |
| COVID-19        | 2-14 Days          | Cough or not, sore throat, Breathless, respiratory failure| Fever, Fever, muscle ache, confusion, headache | Multifocal patchy GGOs with subpleural distribution. Diffused heterogeneous consolidation with GGO | 4, 33, 81 | PittCoVax          | University of Pittsburgh School of Medicine | Vaccine candidate using microneedle transdermal for COVID-19. Testing in mice produced antibodies over a 2-week period. |
| COVID-19        | 2-14 Days          | Cough or not, sore throat, Breathless, respiratory failure| Fever, Fever, muscle ache, confusion, headache | Multifocal patchy GGOs with subpleural distribution. Diffused heterogeneous consolidation with GGO | 4, 33, 81 | Infectious Bronchitis Virus Vaccine | MIGAL | Pre-clinical trials |
| COVID-19        | 2-14 Days          | Cough or not, sore throat, Breathless, respiratory failure| Fever, Fever, muscle ache, confusion, headache | Multifocal patchy GGOs with subpleural distribution. Diffused heterogeneous consolidation with GGO | 4, 33, 81 | APo101 (APERION Biologics) | Phase I | Phase 1 human clinical trials are expected to begin in April 2020. |
| COVID-19        | 2-14 Days          | Cough or not, sore throat, Breathless, respiratory failure| Fever, Fever, muscle ache, confusion, headache | Multifocal patchy GGOs with subpleural distribution. Diffused heterogeneous consolidation with GGO | 4, 33, 81 | TNA-1800 (Tonix Pharmaceuticals) | Initial evaluation | Initial evaluation |
| COVID-19        | 2-14 Days          | Cough or not, sore throat, Breathless, respiratory failure| Fever, Fever, muscle ache, confusion, headache | Multifocal patchy GGOs with subpleural distribution. Diffused heterogeneous consolidation with GGO | 4, 33, 81 | SAR-39 (InnateRx Pharmaceuticals) | Initial evaluation | Initial evaluation |

High-risk groups:
The data on risk factors of virus contraction and disease severity is limited. Currently available evidences stratify various groups of patients with high propensity of disease contraction and severity. These include advanced age (≥ 65 years), obesity, population living in long-term care facilities (e.g. nursing homes), patients with chronic respiratory diseases such as asthma, cardiac diseases, immunocompromised population including those with underlying malignancies, and patients with comorbid conditions such as Diabetes mellitus, hypertension, liver disease or renal failure.36,37

Diagnosis and differential diagnosis:
Like SARS and MERS, the diagnosis of COVID-19 is based on contact and travel history along with laboratory testing. Diagnostic investigations revolve around viral culture, serology and molecular methods. Molecular methods include real-time PCR which examines viral RNA in sputum, nasopharyngeal aspirate, oropharyngeal swabs, bronchoalveolar lavage or deep tracheal aspirate. Samples from the lower respiratory tract contain higher viral load and genome fraction relative to the samples from the upper respiratory tract. This method aids in quick evaluation of results, quantifies the viral load and illustrates genome fraction.19 Compared to the molecular method, sensitivity of antibody detection is lower. Moreover, antibody detection is usually used retrospectively during the diagnosis. Viral culture is more time-taking process and only useful in the initial stages of outbreaks when other diagnostic methods are not readily available. Culture methods are also very useful for in-vitro and in-vivo trials of antiviral drugs or vaccines.17

Table IV: Potential vaccines and drugs for COVID-19.18,20,21

| Vaccines and Drugs | Company Name | Current Status of development |
|--------------------|--------------|-------------------------------|
| IFV-4800 (Inovio Pharmaceuticals) | Phase 1 human clinical trials are expected to begin in April 2020. |
| mRNA-1273 (Moderna Inc.) | Phase 1 human clinical trials have been initiated in 45 healthy volunteers. |
| mRNA vaccine (CureVac) | Vaccine under development |
| mRNA vaccine BNT162 (BioNTech and Pfizer) | mRNA-based vaccine candidate initiated. |
| COVID-19 S-Trimer (GlaxoSmithKline and Clove Biopharmaceuticals) | Preclinical development is started using GSK’s adjuvants (compounds that enhance vaccine efficacy) and Clove’s proprietary proteins, which stimulate an immune response. |
| SARS-COV-2 vaccine (Johnson & Johnson) | Partnering with the Biomedical Advanced Research and Development Authority to develop vaccine candidate. |
| Live-attenuated vaccine (Cohagenix) | Co-develop a live-attenuated vaccine. |
| PCR-based DNA vaccine (Applied DNA Sciences and Takis Biotech) | Designed four COVID-19 vaccine candidates using PCR-based DNA manufacturing systems for preclinical testing in animals. |
| Intranasal COVID-19 vaccine (Allimmune, Inc) | Design and synthesis has been completed and soon start animal testing. |
| HaloVax (Hoth Therapeutics; Voltron Therapeutics) | Collaborate with the Vaccine and Immunotherapy Center of the Massachusetts General Hospital for rapid development of vaccine. |
| PittCoVax (University of Pittsburgh School of Medicine) | Vaccine candidate using microneedle transdermal for COVID-19. Testing in mice produced antibodies over a 2-week period. |
| Infectious Bronchitis Virus vaccine (MIGAL) | Pre-clinical trials |
| APo101 (APERION Biologics) | Phase I |
| TNA-1800 (Tonix Pharmaceuticals) | Initial evaluation |
| SAR-39 (InnateRx Pharmaceuticals) | Initial evaluation |
| S-Trimer vaccine (Clover Biopharmaceuticals) | Pre-clinical trials |
| TBC (Vaxart) | Pre-clinical trials |
| Lenomalab (CysDyn) | Phase II for HIV and fast tracked for COVID-19 |
| Linear DNA Vaccine (Applied DNA Sciences and Takis Biotech) | Pre-clinical trials |
| Drugs and their status of Development |
| Chloroquine | In vitro approve |
| Remdesivir | Phase III testing start |
| Hydroxychloroquine | Phase III testing start |
| Favipiravir (viral RNA polymerase inhibitor) | Investigation stage |
| Sarilumab (Interleukin-6 inhibitors) | Initiation of a phase II/III trial |
| Azudine (nucleoside reverse transcriptase inhibitor) | Investigation stage |
| Darunavir (NS3/4A HCV protease inhibitor) | Investigation stage |
| Yradipiant (neurokinin-1 (NK-1) receptor antagonist) | Phase III |
| Inilumab (anti-tumor necrosis factor receptor 3 (TNFR-3) agonist) | Potential treatment for COVID-19 |
| Inhaled nitric oxide | Phase II study of NO is underway in patients with COVID-19 with the goal of preventing disease progression |
| Ifenprodil (N-methyl-D-aspartate receptor glutamate receptor antagonist) | Start clinical trials for COVID-19 and acute lung injury |
| Anti-SARS-CoV-2 polyclonal hyperimmune globulin | Under development to treat high-risk patients |

It is pertinent to mention that COVID-19 shares most of the clinical manifestations of common cold, influenza, MERS and SARS. In this context, differential diagnosis is of utmost importance.
particularly during the current pandemic. Table (III) demonstrates the differentiating characteristics between these five closely related viral infections.

**Complications:**

Complications of COVID-19 include secondary infections, acute heart damage, pneumothorax and acute respiratory distress syndrome. Complications are more profound among patients with pre-existing comorbid illnesses. However, there is a dearth of investigations evaluating the long-term intricacies of the COVID-19.

**Routes of transmission:**

The transmission of COVID-19 shares similar pathways as for other respiratory viruses. It can transmit through air droplets from cough and sneezing. The initial cases with history of visiting wet market suggest animal to human transmission and subsequent spread of the disease confirms human to human transmission. Both symptomatic and asymptomatic patients have been observed as potential sources of virus. Analysis of stool of COVID-19 patients revealed the presence of SARS-CoV-2 nucleic acid. Moreover, various other studies have also demonstrated that the transmission can also occur through faecal-oral route.

Viruses also spread through inanimate objects, also referred as fomites, which include door handles, clothes and respirators. Fomite transmission of disease is also observed during the current pandemic. In line to these studies, frequent hand washing (at least 20 seconds), sanitization and precautionary measures were suggested for the general public.

A study conducted by Chen et al. among pregnant women having confirmed diagnosis of COVID-19. The vertical transmission by intrauterine route was assessed by testing neonates’ cord blood, amniotic fluid and throat swab samples. However, the results were negative and there is no evidence of vertical and intrauterine transmission of SARS-CoV-2. Furthermore, the exposure levels of faecal contamination, aerosol transmission, and close contact with the mother could boost neonatal COVID-19 infected pneumonia in neonates. So far, there are no reports of COVID-19 through blood contact. Recent studies also suggest the risk of transmission through aerosol. Aerosol transmission is well documented for influenza and it is suggested that improvement in design of ventilation and avoidance aerosol generation can reduce the transmission. However, there is no evidence for aerosol-based transmission but the odds of such transmission is higher among healthcare professionals.

**Treatments:**

Currently, there is no specific treatment or vaccines available for COVID-19. Certain drugs are being tested in-vitro and some drugs are in variable stages of clinical trials on MERS-CoV and SARS-CoV. Studies which evaluated interferon types (I and II) for their antiviral activity show that Interferon-beta (IFNb) had the most potent activity against MERS-CoV, reducing replica-
tion of COVID-19.\textsuperscript{22,23} It will likely take more than a year for the vaccines to be approved and publicly available. Table (IV) elaborates potential candidates for COVID-19 vaccine and their current status of development.

**Prevention:**

China was the first country initiating the vigorous preventive measures for COVID-19. The effectiveness of these measures taken by the Chinese health authorities is attributed to their past experience with SARS outbreak in 2003-2004. These measures included restricted public transport, travels and migration. Moreover, they informed public to use effective personal protection such as masks during the outbreak. The disease spillover to healthcare professionals and hospital staff was also reported during SARS outbreak. The primary precautionary measure for health professionals was the use of personal protective equipment (PPE) including gloves, N95 respirators and eye shields.\textsuperscript{31}

Several measures should be taken to contain the infection including timely publication of information related to the epidemics, early diagnosis, reporting, isolation and provision of supportive treatment. However, prevention of public panic towards outbreak is of paramount importance. Centre for Disease Control and Prevention (CDC) recommends measures similar to those for common cold and flu, such as frequent hand wash with soap for at least 20 seconds or hand sanitization, use of disinfectants and avoiding close contact with known or suspected cases. Precautionary steps are also necessary in healthcare system such as the timely and sufficient supply of medicines, PPE and other hospital supplies necessary for virus containment and care of patients.\textsuperscript{17}

Currently, prevention is the primary strategy to reduce the spread of COVID-19 among people. Patients’ isolation and infection control measures have been adopted by the various countries experiencing the outbreak. Moreover, suitable protective methods must also be utilized during the diagnosis and clinical care of patients. Droplet, airborne and contact precautions are of paramount importance while collecting samples and sputum induction.

General recommendations issued by the WHO, which were later endorsed by various other organisations, are described below:

- Avoid contact with respiratory infection patients.
- Frequent handwash (at least 20 seconds).
- Avoid contact with wild animals.
- Cover coughs with disposable tissues and immediate handwashing following cough.
- Hygienic measures should be taken for the control of infection and prevention.
- Immunocompromised patients should not attend any gatherings.
- Use sanitiser where handwash with soap is not possible.
- Paramedical staff should wear face masks, gowns, gloves and eye protection to prevent pathogens’ transmission.

**Role of pharmacist:**

Pharmacists are most accessible healthcare professional around the globe. Community pharmacists are vital healthcare providers during the outbreak; they remain on the frontline of public health by serving as direct points of access for their patients. Moreover, hospital pharmacists are playing pivotal role in provision of patient care and support.\textsuperscript{66} Pharmacists are responsible for provision of standardised, ethical and optimal care to the public. Moreover, public outreach to the pharmacists is easy and does not bear any cost, particularly during the near enough global lockdown. However, prevention and control practices must be implemented in the pharmacies before educating the public.\textsuperscript{61} International Pharmaceutical Federation (FIP) stressed the active involvement of hospital and community pharmacists to contain the SARS-CoV-2. During the current lockdown which has been imposed by numerous countries, there seems to be an even greater dependence on pharmacists as the first point of contact to fulfill the public’s healthcare needs.\textsuperscript{63} The primary responsibilities of pharmacists may include but not limited to maintenance of drug inventory at appropriate levels, promotion of hand and personal hygiene, in-hospital infection control measures, provision of care and support to the patients, education of paramedics and nurses and arrangements to counter drug shortages. Community pharmacist can play a crucial role in early detection and prevention of new cases by reporting suspects to the healthcare authorities. Since research on the management of COVID-19 is quite dynamic amid rapid publications, pharmacists can serve as potential source of information on treatment and care of COVID-19 patients. As opportunistic infections can occur during the course of COVID-19, hospital pharmacists should have updated information on identifying and managing such infections.\textsuperscript{63,64} Moreover, being an expert of drugs, pharmacists can actively involve in drug and vaccine discovery. The clinical care of COVID-19 patients is of utmost priority for healthcare providers. Pharmacists may assist in developing and implementing treatment guidelines or algorithm in accordance with the updated protocols.\textsuperscript{62} In addition, pharmacists working in drug regulatory authorities should ensure the uncut supply of medications, particularly those that are being used in the care of COVID-19 patients.

**Preparedness for future events:**

World has witnessed three attacks of coronaviruses including SARS-CoV (which emerged in 32 countries) MERS-CoV in 2013 and COVID-19 in 2019. These outbreaks posed serious challenges to healthcare system to contain the virus and it might be attributed to the novel nature of these viruses during the epidemics. COVID-19 has caused quadruple damage to overwhelmed healthcare system in the developing countries. However, many developed nations with sophisticated health system responded well during the current pandemic. The unavailability of medicines and vaccines pose serious risks of future events which might be new emergence or re-emergence. The global collaboration and effort of the scientific community in this time is unprecedented but further research is necessary to find ways to combat the growing encumbrance of infection. Considering the existing and previous outbreaks, similar future
outbreaks are inevitable. However, health authorities around the globe can decrease the damage of similar future events by getting lessons from the current pandemic. Implementing effective precautionary measures, reinforcing and developing epidemiological forces or systems to detect potential pathogens at initial stages of zoonotic emergence after cross-species transmission and preventing the further transmission in population can go a long way to strengthen the infection control. Authorities should also implement strict rules banning wild-life trade and live animal wet markets where human-animal interaction increases the risk of cross-species transfer and zoonotic disease emergence. These sources of viruses must be under the control of health authorities in a similar way as for slaughterhouse around the world. Since researchers have gained much control on bacterial infections, future investigations must be tailored to the viral diseases as most of them lack specific treatments amid variations in viral structures.

Health authorities around the globe should focus their efforts on vertical programmes for the control of zoonotic diseases, coordination and closer integration of health departments, collaboration with intergovernmental organisations such as the World Organization for Animal Health (OIE), implementation and monitoring of policies for effective surveillance, fostering of collaboration among infectious disease researchers, and informative campaigns that target the general public and healthcare professionals. Moreover, collaborative efforts among countries experiencing the COVID-19 outbreak will further strengthen the infection control efforts.

**CONFLICT OF INTEREST:**
All the authors declared no conflict of interest.

**AUTHORS' CONTRIBUTION:**
AA, MHB, THM: Conception or design of the work.
SM, MHB, NHA: Analysed or interpreted the data for the work.
AA, MHB, YHK: Drafted the work.
THM, YHK, NHA: Revised the manuscript critically for important intellectual content.
SM, AA, MHB, YHK, NHA, THM: Provided approval for publication of the content.

**REFERENCES**

1. van der Hoek L, Pyrc K, Jubbink MF, Vermeulen-Oost W, Berkhourt RJM, Wolthers KC, et al. Identification of a new human coronavirus. Nature Med 2004; 10(4):368-73.
2. Guy JS, Breslin JJ, Breuhaus B, Vivrette S, Smith LG. Characterization of a coronavirus isolated from a diarrheic foal. J Clin Microbiol 2000; 38(12):4523-26.
3. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3):181-92.
4. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395(10223):514-23.
5. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 1-4.
6. Galbadage T, Peterson BM, Gunasekera RS. Does COVID-19 Spread Through Droplets Alone? Front Public Health 2020; 8:1-4.
7. Mackenzie JS, Smith DW. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't. Microbiol Aust 2020; 41(1):45-50.
8. Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology 2020; 200274.
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497-506.
10. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727-33.
11. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 1-5.
12. Organization WH. Rolling updates on coronavirus disease (COVID-19): WHO; March, 2020. [Available from: http://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen].
13. Rothen HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020: 102433.
14. McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). UpToDate, retrieved from http://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-epidemiology-virology-clinical-features-diagnosis-and-prevention (Accessed on March 27, 2020).
15. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology 2020; 295(3):715-21.
16. Guo Y, Huang Y, Huang J, Jin Y, Jiang W, Liu P, et al. COVID-19 Pandemic: global epidemiological trends and China’s subsequent preparedness and responses. Zhonghua Liu Xing Bing Xue Zazhi 2020; 41(5):643.
17. Sahin AR, Erdogan A, Aqaooglu PM, Dineri Y, Cakirci AY, Senel ME, et al. 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. EMJ MO 2020; 4(1):1-7.
18. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses 2020; 12(2):135.
19. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N England J Med 2020; 382:727-33.
20. Perlman S. Another decade, another coronavirus. Mass Medical Soc 2020; 760-62.
21. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PloS Pathogens 2018; 14(8):e1007236.
22. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and treatment coronavirus (COVID-19). StatPearls [Internet]: StatPearls Publishing; 2020.
23. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224):565-74.
24. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2
and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020; **181**(2):271-80.

25. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus in Wuhan, China: a descriptive study. *Lancet* 2020; **395**(10223):507-13.

26. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020; **367**(6483):1260-63.

27. Federation IP. COVID-19: Guidelines for pharmacists and the pharmacy workplace; 2020.

28. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Battle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. *J Am Soc Nephrol* 2006; **17**(11):3067-75.

29. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci* 2020; **12**(1):1-5.

30. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen K-Y. Coronaviruses—drug discovery and therapeutic options. *Nat Rev Drug Discov* 2016; **15**(5):327.

31. Perico L, Benigni A, Remuzzi G. Should COVID-19 Concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. *Nephron* 2020; 1-9.

32. Chen Z, Zhang W, Lu Y, Guo C, Guo Z, Liao C, et al. From SARS-CoV to Wuhan 2019-nCoV Outbreak: Similarity of early epidemic and prediction of future trends. *Cell Host Microbe*; 2020.

33. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents* 2020; 55:1-9.

34. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. *J Med Virol* 2020; **94**(4):441-7.

35. Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. *Radiology* 2020; 200236.

36. Jordan R, Adab P, Cheng K. Covid-19: risk factors for severe disease and death. *BMJ* (Clinical Research ed). 2020;368:1198-99.

37. Prevention CFDCA. Coronavirus Disease 2019 (COVID-19) 2020 [Available from: http://www.cdc.gov/coronavirus/2019n cov/specific-groups/people-at-higher-risk.html].

38. Holshue ML, DeBold C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med* 2020; **382**:929-36.

39. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; **382**(18):1708-20.

40. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA* 2020; **323**(18):1843-44.

41. Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol* 2020; **5**(5):434-35.

42. Kraay AN, Hayashi MA, Hernandez-Ceron N, Spicknall IH, Eisenberg MC, Meza R, et al. Fomite-mediated transmission as a sufficient pathway: a comparative analysis across three viral pathogens. *BMC Infect Diseases* 2018; **18**(1):1-13.

43. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. *Lancet* 2020; **395**(10226):809-15.

44. Meng L, Hua F, Bian Z. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. *J Dent Res* 2020; 99(5):817-87.

45. Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: a commentary. *BMC Infect Dis* 2019; **19**(1):1-9.

46. Wong BC, Lee N, Li Y, Chan PK, Qiu H, Luo Z, et al. Possible role of aerosol transmission in a hospital outbreak of influenza. *Clin Infect Dis* 2010; **51**(10):1176-83.

47. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Case report Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. *Antiviral Ther* 2016; **21**:455-59.

48. Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, Aljohani S, Al Harbi S, et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): Study protocol for a randomized controlled trial. *Trials* 2018; **19**(1):1-8.

49. Jordan PC, Liu C, Raynaud P, Lo MK, Spiropoulou CF, Symons JA, et al. Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. *PLoS Pathogens* 2018; **14**(2):1-23.

50. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature* 2016; **531**(7594):381-85.

51. Brown AJ, Won JJ, Graham RL, Dinnon III KH, Sims AC, Feng JY, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. *Antiviral Res* 2019; **169**:1-10.

52. Cockrell AS, Yount BL, Scobey T, Jensen K, Douglas M, Beall A, et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nat Microbiol* 2016; **2**(2):1-11.

53. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering* 2020; 1-7.

54. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 2020; 1-8.

55. Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrobial Agents*. 2020; 1-24.

56. Mahendra Pal GB, Chaltu Desalegn, Venkataramana Kandi.
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. *Cureus* 2020; **12**(3):1-13.

57. Caly L, Drule JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* 2020; 1-4.

58. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* 2020; **323**(16):1582-89.

59. Cahill J. Potential COVID-19 therapeutics currently in development 2020 [Available from: http://www.europeanpharmaceuticalreview.com/article/115842/potential-covid-19-therapeutics-currently-in-development/]

60. Bukhari N, Rasheed H, Nayyer B, Babar Z. Pharmacists at the forefront beating the COVID-19 pandemic. *J Pharmaceut Pol* 2020; 13:8-10.

61. Ung CO. Community pharmacist in public health emergencies: Quick to action against the coronavirus 2019-nCoV outbreak. *Res Soc Adm Pharm* 2020; **16**(4):583-86.

62. Li H, Zheng S, Liu F, Liu W, Zhao R. Fighting against COVID-19: innovative strategies for clinical pharmacists. *Res Soc Adm Pharm* 2020; 1-6.

63. Khan Z, Muhammad K, Ahmed A, Rahman H. Coronavirus outbreaks: prevention and management recommendations. *Drugs Ther Resp Perspect* 2020; 1-3.

64. Federation IP. *COVID-19: Guidelines for Pharmacists and the Pharmacy Workforce: FIP*; 2020 [Available from: http://www.fip.org/files/content/priority-areas/coronavirus/COVID-19-Guidelines-for-pharmacists-and-the-pharmacy-workforce.pdf]

65. Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. *Trends Microbiol* 2016; **24**(6):490-502.

66. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. *Proc Soc Exp Biol Med* 1966; **121**(1):190-93.

67. Van Der Hoek L, Pyrc K, Berkhourt B. Human coronavirus NL63, a new respiratory virus. *FEMS Microbiol Rev* 2006; **30**(5):760-73.

68. Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. *J Virol* 2005; **79**(2):894-95.

69. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. *Proc Natl Acad Sci U S A* 1967; **57**(4):933.

70. Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. *N Eng J Med* 2003; **349**(25):2431-41.

71. Zaki AM, Van BoheecD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Eng J Med* 2012; **367**(19):1814-20.

72. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: A statistical analysis of publicly available case data. *J Clin Med* 2020; **9**(2):1-9.

73. Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *Int J Surgery* 2020; **76**:71-6.

74. Organization WH. Coronavirus disease 2019 (COVID-19) Situation Report – 69: WHO; 2020 [Available from: http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200329-sitrep-69-covid-19.pdf]

75. Duan Y-n, Qin J. Pre-and posttreatment chest CT findings: 2019 novel coronavirus (2019-nCoV) pneumonia. *Radiology* 2020; 295:21.

76. Roush SW, McIntyre L, Baldy LM. Manual for the surveillance of vaccine-preventable diseases. Atlanta. *Centers Disease Control Prevent* 2008; 4:1-9.

77. Franquet T. Imaging of pulmonary viral pneumonia. *Radiology* 2011; **260**(1):18-39.

78. Lee KS. Pneumonia Associated with 2019 Novel Coronavirus: Can computed tomographic findings help predict the prognosis of the disease? *Korean J Radiol* 2020; **21**(3):257-58.

79. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. *Lancet* 2015; **386**(9997):995-1007.

80. Hansell DM, Bankier AA, MacMahon H, McCloud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. *Radiology* 2008; **246**(3):697-722.

81. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med* 2020.

82. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov Ther* 2020; **14**(1):58-60.

83. McCreary EK, Pogue JM, editors. *Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options*. Open Forum Infectious Diseases; 2020: Oxford University Press.